Clinical trials
Pulmonary clinical trials
Below are recruiting pulmonary clinical trials, each written for real people, not researchers. We’re tracking 1,310 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07587658RecruitingPhase 4
Dupilumab after a severe COPD flare-up
This study tests whether adding the drug dupilumab to usual hospital care for a severe COPD flare-up helps patients recover better than usual care alone. It is for adults with a specific type of inflammation in their blood, and may reduce the chance of future flare-ups.
Mullica Hill, New JerseyAges 40 years+ - NCT05798923RecruitingPhase 2
Study of a new drug for pulmonary hypertension with lung disease
This trial tests an investigational drug called LAM-001 for people who have pulmonary hypertension (high blood pressure in the lungs) along with a type of lung disease called interstitial lung disease. The drug may help improve symptoms and daily function. This study will see if the drug is safe and helpful for this condition.
Tucson, ArizonaAges 18–85 - NCT07612878Recruiting
Registry tracking COPD patients starting dupilumab treatment
This is a registry—an observational study tracking patients with COPD (chronic lung disease) who are newly starting a medication called dupilumab. Researchers will follow your health outcomes to learn how well this treatment works in real-world practice.
Indianapolis, IndianaAges 40 years+ - NCT07132788Recruiting
Study of pulmonary arterial hypertension and lean muscle mass
This study looks at how pulmonary arterial hypertension (PAH) affects lean muscle mass. It aims to understand the relationship between PAH and muscle loss, which could help improve treatments and quality of life.
Philadelphia, PennsylvaniaAges 18 years+ - NCT02527486Recruiting
Airways registry study for people with COPD symptoms
This registry collects information from people with COPD (and sometimes overlapping asthma-COPD features) to better understand breathing problems and airways behavior. It may help researchers learn which patterns match different symptom types, without necessarily using a new drug.
Seongnam-si, Gyeonggi-doAges 20–90 - NCT03120481Recruiting
Check how respiratory health changes in people without lung problems
This trial enrolls adults who recently had a chest X-ray as part of routine health screening and did not show major abnormal findings, and who do not have significant breathing symptoms. It may help researchers understand changes in respiratory health over time and improve how respiratory disease risk is monitored.
Seoul, SeoulAges 19–90 - NCT04160715Recruiting
Registry for people with idiopathic pulmonary fibrosis in Korea
This study is a registry that collects health information from people diagnosed with idiopathic pulmonary fibrosis (IPF). It may help researchers better understand IPF and how it changes over time, even if it doesn’t involve a new medication.
Seongnam-siAges 30–100 - NCT04665674Recruiting
Study of adults with pulmonary Langerhans cell histiocytosis
This study follows adults with a specific lung condition to better understand how it behaves over time. If you have the right diagnosis, joining could help researchers learn what to expect and how to manage it.
ParisAges 18 years+ - NCT03269630Recruiting
Pulmonary hypertension biobank for heart-lung blood samples
This study collects and stores health information and possibly blood samples from people being evaluated for pulmonary hypertension or related autoimmune conditions. It helps researchers learn more about these illnesses and may support future studies.
New Orleans, LouisianaAges 18 years+ - NCT05610631Recruiting
Switzerland heart-lung pressure registry for people with PH
This is a registry that collects information from people who have pulmonary hypertension (high blood pressure in the lungs). It helps researchers better understand the condition and may support future studies.
ZurichAges Any age - NCT04355975Recruiting
Study follow-up outcomes after a lung blood clot
This trial looks at how people do after an acute pulmonary embolism (a blood clot in the lungs). It aims to understand real-world outcomes over follow-up and may help improve how care teams track patients after treatment.
Bern, Canton of BernAges Any age - NCT03014609Recruiting
Testing cardiovascular risk in people with COPD
This trial studies cardiovascular (heart and blood vessel) risk in people who have stable COPD or a recent worsening of COPD. It may help researchers understand which risks to monitor during and after a COPD flare and how to prevent complications.
Grenoble, La TroncheAges 18–85 - NCT05665556Recruiting
Registry for pulmonary hypertension in connective tissue disease
This trial is a registry that collects health information from people with certain types of pulmonary hypertension linked to connective tissue diseases. It helps doctors understand patterns of disease and outcomes, which can guide future care and studies.
Mexico CityAges 18 years+ - NCT05937191RecruitingPhase 1/Phase 2
Leflunomide for childhood idiopathic lung bleeding
This trial tests whether leflunomide can safely help children with idiopathic pulmonary hemosiderosis (a condition where the lungs bleed, and iron builds up). The study is mainly about safety and early signs of benefit in young patients.
Guangzhou, GuangdongAges 5 months–18 years - NCT03169010Recruiting
Study registry for rare lung artery blood pressure problems
This study collects information from people with rare types of pulmonary hypertension (high blood pressure in the lungs) and from healthy volunteers. It helps researchers better understand these conditions, especially using a special lung-heart test to confirm the diagnosis.
Beijing, Beijing MunicipalityAges Any age - NCT03916302Recruiting
Pulmonary embolism registry study in Warsaw
This study keeps a registry (record) of people with a confirmed pulmonary embolism. Your information helps doctors better understand the condition and improve care.
WarsawAges 18 years+ - NCT06127641Recruiting
Rehabilitation for lung disease after tuberculosis
This trial tests a pulmonary rehabilitation program for people who have ongoing lung problems after being treated for tuberculosis. It aims to help improve their breathing and physical function.
Rio de JaneiroAges 18 years+ - NCT07428785Recruiting
Measuring lung and blood volume in COPD
This study looks at how COPD affects the amount of air your lungs can hold and the total blood in your body. The goal is to better understand the disease, which may help improve future treatments.
CopenhagenAges 45–80 - NCT06078436Recruiting
Early carvedilol for heart failure shock
This trial tests whether starting the heart failure medication carvedilol early, along with standard monitoring, can help people in cardiogenic shock (when the heart can't pump enough blood) due to a weak heart muscle. It aims to see if earlier treatment improves outcomes.
SeoulAges 19 years+ - NCT06189820RecruitingPhase 2
FAP protein as a marker for fibrotic lung disease
This trial is looking at a protein called FAP in the blood of people with fibrotic lung diseases. It aims to understand how this protein might be used as a marker to help doctors better diagnose and track these conditions.
BrusselsAges 18 years+ - NCT06198309Recruiting
Predicting worsening COPD in severe patients
This study builds a tool to predict which COPD patients are likely to have worsening symptoms. It may help your doctor better manage your care if you have severe COPD.
Beijing, Beijing MunicipalityAges 40–85 - NCT04715425Recruiting
Surgery vs catheter procedure for persistent atrial fibrillation
This trial compares two ways to treat persistent atrial fibrillation: a minimally invasive surgery approach versus a catheter ablation. It may help people find the most effective option to reduce ongoing abnormal heart rhythm and avoid repeat procedures.
AmsterdamAges 18–80 - NCT07868419RecruitingPhase 3
Nalbuphine tablets for chronic cough in pulmonary fibrosis
This trial tests an extended-release tablet called nalbuphine to reduce chronic coughing in people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring and often leads to a persistent cough. If you have IPF and have been coughing for at least 8 weeks, this study may help manage that symptom.
Wilmington, DelawareAges 40 years+ - NCT06265350Recruiting
Freezing lung tumors plus immunotherapy for liver cancer with lung spread
This study tests a combination of treatments—freezing the lung tumors (cryoablation) plus two drugs (cardonilizumab and bevacizumab)—for people with liver cancer that has spread only to their lungs. It may be an option if your first treatment stopped working but your liver tumors are under control.
Guanzhou, GuangdongAges 18–75
Hear when a new Pulmonary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pulmonary?
- Yes. Clin2 currently lists 1,310 recruiting pulmonary studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pulmonary trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pulmonary trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.